Related Experiment Videos
[Neonatal chylothorax and conservative treatment]
E Martínez Tallo1, R Hernández Rastrollo, E Agulla Rodiño
1Servicio de Pediatría, Hospital Universitario Materno-Infantil Infanta Cristina, Badajoz, Spain. mtallo@mx3.redestb.es
Anales Espanoles De Pediatria
|June 4, 2002
Summary
Congenital chylothorax in infants has a favorable prognosis with conservative management including pleural taps and nutritional support. Post-surgical chylothorax, however, carries a high mortality rate due to complications.
Area of Science:
- Pediatric Surgery
- Neonatology
- Thoracic Medicine
Context:
- Chylothorax, a rare condition involving lymphatic fluid in the pleural space, presents diagnostic and therapeutic challenges in neonates.
- Congenital and postsurgical etiologies of chylothorax require distinct management approaches and have different prognoses.
Purpose:
- To report on four cases of chylothorax, detailing the clinical course, management strategies, and outcomes.
- To review the etiology, clinical features, and treatment outcomes of chylothorax in pediatric patients.
Summary:
- Three cases of congenital chylothorax, two diagnosed prenatally, showed favorable outcomes with conservative treatment (pleural taps, parenteral/enteral nutrition with medium-chain triglycerides), resolving within 19-80 days.
- One case of postsurgical chylothorax following esophageal atresia repair resulted in rapid, high-volume pleural effusion and mortality due to intestinal complications and multiorgan failure.
- Conservative management for congenital chylothorax included respiratory support, pleural drainage, and specialized nutrition, leading to resolution without recurrence over 1-6 years.
Impact:
- Highlights the generally positive prognosis of congenital chylothorax with appropriate conservative care.
- Underscores the critical, often fatal, risk associated with postsurgical chylothorax, emphasizing the need for vigilant monitoring and prompt intervention.
- Provides insights into effective nutritional strategies, including medium-chain triglyceride formulas, for managing chylothorax.